Výsledky vyhledávání

Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension

Autor: Hisashi Kawata, Makoto Aihara, Noriko Odani-Kawabata, Fenghe Lu, Akihiro Iwata, Naveed K Shams

Publikováno v: American Journal of Ophthalmology. 220:53-63

Purpose To evaluate the efficacy and safety of omidenepag isopropyl (OMDI), a selective, non-prostaglandin, prostanoid EP2 receptor agonist, in Japanese patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT). Design Phase III,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::615c1c847eac80b5c72a17ffb92ab991
https://doi.org/10.1016/j.ajo.2020.06.003

Zobrazit plný text záznamu

Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)

Autor: Fenghe Lu, Makoto Aihara, Kenzo Yamamura, Noriko Odani-Kawabata, Yuki Tanaka, Naveed K Shams, Hisashi Kawata

Publikováno v: Journal of Ocular Pharmacology and Therapeutics

Purpose: Omidenepag isopropyl (OMDI) is a prodrug of OMD, a selective, nonprostaglandin, prostanoid EP2 receptor agonist. This phase I study aimed to investigate the pharmacokinetic properties, safety, and intraocular pressure (IOP)-lowering efficacy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1570f9357ec6e5e22a9c48f986cc2745
http://europepmc.org/articles/PMC6918846

Zobrazit plný text záznamu

A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)

Autor: Noriko Odani-Kawabata, Michelle Sato, Phillip Dinh, Marc A Abrams, Fenghe Lu, Kenneth Olander, Almira Chabi, Gary Jerkins, Naveed K Shams

Publikováno v: Journal of Glaucoma

Prcis No significant difference was found between the intraocular pressure (IOP) lowering of omidenepag isopropyl 0.002% once daily (QD) and twice daily (BID). However, adverse events (AEs) were higher in the BID arm; thus, QD dosing is the preferred

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f2fd8b013e3f4733e4d132b49834a4a
https://pubmed.ncbi.nlm.nih.gov/33813559

Zobrazit plný text záznamu

Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study

Autor: Makoto, Aihara, Fenghe, Lu, Hisashi, Kawata, Akihiro, Iwata, Noriko, Odani-Kawabata, Naveed K, Shams

Publikováno v: American journal of ophthalmology. 220

To evaluate the efficacy and safety of omidenepag isopropyl (OMDI), a selective, non-prostaglandin, prostanoid EP2 receptor agonist, in Japanese patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT).Phase III, randomized, inve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0cc9527817e02b140f6b5f5efb65a4e7
https://pubmed.ncbi.nlm.nih.gov/34462073

Zobrazit plný text záznamu

Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study

Autor: Akihiro Iwata, Hisashi Kawata, Auli Ropo, Fenghe Lu, Makoto Aihara, Noriko Odani-Kawabata, Naveed K Shams

Publikováno v: Japanese journal of ophthalmology. 64(4)

Omidenepag isopropyl (OMDI) is the prodrug of omidenepag, a selective, non-prostaglandin, prostanoid EP2 receptor agonist, which has been shown to lower intraocular pressure (IOP) in patients with glaucoma and ocular hypertension (OHT). This study ev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51fd1e4bc08bd44908d4f6dfeb2178e7
https://pubmed.ncbi.nlm.nih.gov/32572719

Zobrazit plný text záznamu

Akademický článek

A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6).

Autor: Olander, Kenneth W., Sato, Michelle A., Abrams, Marc A., Jerkins, Gary W., Fenghe Lu, Dinh, Phillip, Odani-Kawabata, Noriko, Chabi, Almira, Shams, Naveed K.

Publikováno v: Journal of Glaucoma; Jun2021, Vol. 30 Issue 6, p473-480, 8p

Zobrazit plný text záznamu

Akademický článek

The relationship between the treatment zone diameter and visual, optical and subjective performance in Corneal Refractive Therapy™ lens wearers.

Autor: Fenghe Lu^1,2, Simpson, Trefford¹ tsimpson@uwaterloo.ca, Sorbara, Luigina¹, Fonn, Desmond¹

Publikováno v: Ophthalmic & Physiological Optics. Nov2007, Vol. 27 Issue 6, p568-578. 11p. 2 Charts, 10 Graphs.

Zobrazit plný text záznamu

Corneal Shape and Optical Performance After One Night of Corneal Refractive Therapy for Hyperopia

Autor: Luigina Sorbara, Fenghe Lu, Desmond Fonn, Trefford Simpson

Publikováno v: Optometry and Vision Science. 84:357-364

To investigate the corneal shape and optical performance following one night of Corneal Refractive Therapy for hyperopia (CRTH).Twenty subjects (spherical equivalent: -2.14 +/- 2.54 D) were fit with a Paragon CRTH lens (Dk = 100) on one eye randomly.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3af2920bbb666854b8b346158c92d396
https://doi.org/10.1097/opx.0b013e3180437e55

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání